---
title: "Claseprubart (DNTH103) in Generalized myasthenia gravis: Diagnosis"
description: "Formulary evidence on Claseprubart (DNTH103) in Generalized myasthenia gravis: Diagnosis. Topics: Clinical diagnosis and confirmatory testing, Antibody testing: AChR antibodies, Antibody testing: MuSK and LRP4 antibodies and seronegative disease, Antibody testing: United States testing patterns after a new diagnosis, and 6 further topics. 10 evidence topics quoted from 8 sources."
canonical: "https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/product-information-and-disease-description/diagnosis"
published: "2026-11-15T22:20:57-05:00"
modified: "2026-11-15T22:20:57-05:00"
---

# Claseprubart (DNTH103) in Generalized myasthenia gravis: Diagnosis

<a id="heading-2.2.1.5"></a>

## 2.2.1.5 Diagnosis

<a id="topic-2.2.1.5-1"></a>

### Clinical diagnosis and confirmatory testing

> “The diagnosis of autoimmune Myasthenia Gravis (MG) remains clinical and rests on the history and physical findings of fatigable, fluctuating muscle weakness in a specific distribution.”
> “Ancillary bedside tests and laboratory methods help confirm the synaptic disorder, define its type and severity, classify MG according to the causative antibodies, and assess the effect of treatment objectively.”

Source: [Rousseff (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8073361/)

> “Diagnosis is straightforward in most patients with typical symptoms and a positive antibody test, although a detailed clinical and neurophysiological examination is important in antibody-negative patients.”

Source: [Gilhus et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31048702/)

<a id="topic-2.2.1.5-2"></a>

### Antibody testing: AChR antibodies

> “In a patient with clinical features of MG, serum testing for AChR-Ab is the first recommended step in diagnosis by most recent guidelines and expert opinions”
> “The test has a very high specificity, so the detection of elevated titers in the appropriate clinical setting is diagnostic of AChR-myasthenia, and further testing may not be necessary”
> “The RIPA for binding Ab is abnormal in up to 85% of adult patients with generalized MG, but only about 50% of patients with ocular MG”
> “The technique detects autoantibodies to clustered AChR in about 15% of RIPA-seronegative MG patients”

Source: [Rousseff (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8073361/)

<a id="topic-2.2.1.5-3"></a>

### Antibody testing: MuSK and LRP4 antibodies and seronegative disease

> “MuSK-Ab are found in about 6–8% of all MG cases”

Source: [Rousseff (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8073361/)

> “In approximately 15% of patients with generalized MG and 50% of patients with ocular MG, both AChR and MuSK antibodies were absent.”
> “Detection rates in double-seronegative patients range from 2% to 50%, depending on the geographical origin, with LRP4-Ab being more frequent in non-Caucasian patients, and on the employed assay, with Live CBA being the most widely used”

Source: [Vinciguerra et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10526522/)

<a id="topic-2.2.1.5-4"></a>

### Antibody testing: United States testing patterns after a new diagnosis

> “Of 5788 cases, 2590 (44.7 %) had at least one valid serology test result: 1453 (56.3 %) seronegative, 1094 (42.4 %) anti-AChR+, 28 (1.1 %) anti-MuSK+, and 5 (0.2 %) anti-LRP4+.”
> “Among the seronegative, 56.6 % were only tested for anti-AChR antibodies, 33.7 % tested both anti-AChR and anti-MuSK antibodies, and 5.0 % tested all three antibodies.”

Source: [Pesa et al. (2026a)](https://pubmed.ncbi.nlm.nih.gov/41455461/)

<a id="topic-2.2.1.5-5"></a>

### Electrodiagnosis: repetitive nerve stimulation

> “In generalized MG, RNS of distal muscles is abnormal in 30–35% of patients, while in proximal muscles, it is abnormal 60–70%”
> “One should note as a standard feature the high specificity of RNS, which reaches about 97% in generalized MG and 94% in ocular MG”

Source: [Rousseff (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8073361/)

<a id="topic-2.2.1.5-6"></a>

### Electrodiagnosis: single-fiber and concentric needle jitter

> “The jitter study is the most sensitive indicator of impaired neuromuscular transmission”
> “The CNE jitter is abnormal in 98–100% in generalized MG and above 90% in ocular MG.”
> “While highest in sensitivity, jitter measurements are not specific and may be abnormal in other synaptic disorders, in denervation and reinnervation processes (poly- and mononeuropathies), some myopathies, and with motor neuron disorder (MND) in particular”

Source: [Rousseff (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8073361/)

<a id="topic-2.2.1.5-7"></a>

### Bedside tests: ice-pack and edrophonium tests

> “The test is used mostly in ocular MG and seems more popular among neuro-ophthalmologists; some authors report sensitivities equal to that of single-fiber electromyography (SFEMG) in patients presenting with ptosis and a very high negative predictive value”
> “However, others note much lower specificity at about 25%”
> “In the USA, edrophonium has been discontinued since 2018”

Source: [Rousseff (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8073361/)

<a id="topic-2.2.1.5-8"></a>

### MGFA clinical classification

| Class | Quoted definition |
| --- | --- |
| Class I | “Any ocular muscle weakness; may have weakness of eye closure. All other muscle strength is normal.” |
| Class II | “Mild weakness affecting muscles other than ocular muscles; may also have ocular muscle weakness of any severity.” |
| Class IIa | “Predominantly affecting limb, axial muscles, or both. May also have lesser involvement of oropharyngeal muscles.” |
| Class IIb | “Predominantly affecting oropharyngeal, respiratory muscles, or both. May also have lesser or equal involvement of limb, axial muscles, or both.” |
| Class III | “Moderate weakness affecting muscles other than ocular muscles; may also have ocular muscle weakness of any severity.” |
| Class IV | “Severe weakness affecting muscles other than ocular muscles; may also have ocular muscle weakness of any severity.” |
| Class V | “Defined as intubation, with or without mechanical ventilation, except when employed during routine postoperative management. The use of a feeding tube without intubation places the patient in class IVb.” |

Source: [Myasthenia Gravis Foundation of America](https://myasthenia.org/wp-content/uploads/Portals/0/MGFA%20Classification.pdf)

<a id="topic-2.2.1.5-9"></a>

### Consensus definitions: treatment goal, remission, crisis, and refractory disease

> “MMS: The patient has no symptoms or functional limitations from MG but has some weakness on examination of some muscles.”
> “Rapid clinical worsening of MG that, in the opinion of the treating physician, could lead to crisis in the short term (days to weeks).”
> “Worsening of myasthenic weakness requiring intubation or noninvasive ventilation to avoid intubation, except when these measures are employed during routine postoperative management”
> “PIS3 is unchanged or worse after corticosteroids and at least 2 other IS agents, used in adequate doses for an adequate duration, with persistent symptoms or side effects that limit functioning, as defined by patient and physician.”

Source: [Sanders et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4977114/)

<a id="topic-2.2.1.5-10"></a>

### Diagnostic delay: United States patients with generalized myasthenia gravis

> “Quantitative surveys and qualitative interviews were conducted (January-May 2023) in patients with gMG (n = 71 surveys; n = 47 interviews) and clinicians in the United States treating patients with gMG (n = 12 surveys and interviews).”
> “Patients had mean (SD) diagnostic journey time of 11.8 (22.5) months from symptom onset to seeking care and 15.5 (36.7) months from seeking care to diagnosis.”
> “Sources of diagnostic journey delay (≥9.9 % patients) were: clinicians mistaking gMG symptoms as female health issues, difficulty accessing specialty care, and lack of gMG knowledge among HCPs.”

Source: [Jiang et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/41319378/)

Additional sources: [Jaretzki et al. (2000)](https://pubmed.ncbi.nlm.nih.gov/10891897/)

## Related pages
- [Claseprubart (DNTH103): Generalized myasthenia gravis](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: Terms and abbreviations](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/terms-and-abbreviations.md)
- [Claseprubart (DNTH103): Generalized myasthenia gravis](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/executive-summary.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: Product information and disease description](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/product-information-and-disease-description.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: Clinical evidence](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/clinical-evidence.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: Economic information and modeling report](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/economics) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/economics.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: References](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/references) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/references.md)
